RU2736831C2 - Плазминоген-заместительная терапия при дефиците плазминогена - Google Patents
Плазминоген-заместительная терапия при дефиците плазминогена Download PDFInfo
- Publication number
- RU2736831C2 RU2736831C2 RU2018120182A RU2018120182A RU2736831C2 RU 2736831 C2 RU2736831 C2 RU 2736831C2 RU 2018120182 A RU2018120182 A RU 2018120182A RU 2018120182 A RU2018120182 A RU 2018120182A RU 2736831 C2 RU2736831 C2 RU 2736831C2
- Authority
- RU
- Russia
- Prior art keywords
- plasminogen
- subject
- activity
- days
- deficiency
- Prior art date
Links
- 108010051456 Plasminogen Proteins 0.000 title claims abstract description 754
- 102000013566 Plasminogen Human genes 0.000 title claims abstract description 749
- 230000007812 deficiency Effects 0.000 title claims abstract description 86
- 238000009256 replacement therapy Methods 0.000 title description 8
- 230000000694 effects Effects 0.000 claims abstract description 314
- 230000002950 deficient Effects 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 64
- 230000002829 reductive effect Effects 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 230000037396 body weight Effects 0.000 claims description 41
- 230000003442 weekly effect Effects 0.000 claims description 27
- 206010012601 diabetes mellitus Diseases 0.000 claims description 26
- 206010010741 Conjunctivitis Diseases 0.000 claims description 25
- 238000002560 therapeutic procedure Methods 0.000 claims description 25
- 239000003146 anticoagulant agent Substances 0.000 claims description 24
- 230000002537 thrombolytic effect Effects 0.000 claims description 24
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 23
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 22
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 22
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 claims description 20
- 230000002354 daily effect Effects 0.000 claims description 20
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 17
- 206010040047 Sepsis Diseases 0.000 claims description 16
- 208000011580 syndromic disease Diseases 0.000 claims description 16
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 15
- 208000034970 Heterotopic Ossification Diseases 0.000 claims description 15
- 208000021798 Hypoplasminogenemia Diseases 0.000 claims description 15
- 230000007941 heterotopic ossification Effects 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 14
- 230000003247 decreasing effect Effects 0.000 claims description 14
- 210000004276 hyalin Anatomy 0.000 claims description 14
- 208000011200 Kawasaki disease Diseases 0.000 claims description 12
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 12
- 208000007257 Budd-Chiari syndrome Diseases 0.000 claims description 10
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 9
- 206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 claims description 9
- 208000007475 hemolytic anemia Diseases 0.000 claims description 9
- 206010069351 acute lung injury Diseases 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 208000020165 Neonatal respiratory disease Diseases 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 59
- 230000035772 mutation Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 17
- 239000003527 fibrinolytic agent Substances 0.000 description 17
- 108010073385 Fibrin Proteins 0.000 description 16
- 102000009123 Fibrin Human genes 0.000 description 16
- 229950003499 fibrin Drugs 0.000 description 16
- 230000003480 fibrinolytic effect Effects 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 210000004379 membrane Anatomy 0.000 description 15
- 230000007423 decrease Effects 0.000 description 14
- 230000003902 lesion Effects 0.000 description 14
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000001802 infusion Methods 0.000 description 13
- 230000005526 G1 to G0 transition Effects 0.000 description 12
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 229960000187 tissue plasminogen activator Drugs 0.000 description 12
- 208000030613 peripheral artery disease Diseases 0.000 description 11
- 229940012957 plasmin Drugs 0.000 description 11
- 108010088842 Fibrinolysin Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 239000004023 fresh frozen plasma Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 210000001508 eye Anatomy 0.000 description 7
- 230000020764 fibrinolysis Effects 0.000 description 7
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 6
- 206010010356 Congenital anomaly Diseases 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 241000233805 Phoenix Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 206010071570 ligneous conjunctivitis Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000003154 D dimer Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 4
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 108010052295 fibrin fragment D Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010003598 Atelectasis Diseases 0.000 description 3
- 206010011071 Coronary artery aneurysm Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000010496 Heart Arrest Diseases 0.000 description 3
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 208000010358 Myositis Ossificans Diseases 0.000 description 3
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 3
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 3
- 102000001938 Plasminogen Activators Human genes 0.000 description 3
- 108010001014 Plasminogen Activators Proteins 0.000 description 3
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000013276 bronchoscopy Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 208000003906 hydrocephalus Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 108010087750 lysyl-plasminogen Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229940127126 plasminogen activator Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 210000002989 hepatic vein Anatomy 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 230000002826 hypofibrinolytic effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011542 limb amputation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000007772 nodular growth Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010073713 Musculoskeletal injury Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 208000021885 Newborn respiratory disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 101150059340 PLG gene Proteins 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000012871 acute dyspnea Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000007214 atherothrombosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007478 fluorogenic assay Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000002830 glycination Effects 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000013792 malformation of the cerebellar vermis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000018341 negative regulation of fibrinolysis Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000037436 splice-site mutation Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011541 total hip replacement Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250235P | 2015-11-03 | 2015-11-03 | |
| US62/250,235 | 2015-11-03 | ||
| PCT/IB2016/001599 WO2017077380A1 (en) | 2015-11-03 | 2016-11-03 | Plasminogen replacement therapy for plasminogen-deficiency |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018120182A RU2018120182A (ru) | 2019-12-04 |
| RU2018120182A3 RU2018120182A3 (enExample) | 2020-04-27 |
| RU2736831C2 true RU2736831C2 (ru) | 2020-11-20 |
Family
ID=58661917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018120182A RU2736831C2 (ru) | 2015-11-03 | 2016-11-03 | Плазминоген-заместительная терапия при дефиците плазминогена |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11291711B2 (enExample) |
| EP (1) | EP3370760B1 (enExample) |
| JP (1) | JP6878423B2 (enExample) |
| KR (1) | KR102821400B1 (enExample) |
| CN (1) | CN108289935A (enExample) |
| AU (1) | AU2016347863B2 (enExample) |
| BR (1) | BR112018008965A8 (enExample) |
| CA (1) | CA3002915C (enExample) |
| FI (1) | FI3370760T3 (enExample) |
| IL (1) | IL258913B (enExample) |
| MX (1) | MX2018005588A (enExample) |
| MY (1) | MY199581A (enExample) |
| RU (1) | RU2736831C2 (enExample) |
| TW (1) | TWI801331B (enExample) |
| WO (1) | WO2017077380A1 (enExample) |
| ZA (1) | ZA201802820B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201722464A (zh) * | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| DK3395354T3 (da) | 2015-12-18 | 2024-06-03 | Talengen Int Ltd | Plasminogen til anvendelse i behandling af diabetisk nefropati |
| EP3395353B1 (en) | 2015-12-18 | 2024-03-06 | Talengen International Limited | Plasminogen for use in treating or preventing diabetes mellitus nerve injury |
| TWI653982B (zh) * | 2015-12-18 | 2019-03-21 | 大陸商深圳瑞健生命科學研究院有限公司 | Method for preventing or treating acute and chronic thrombosis |
| ES2961967T3 (es) | 2015-12-18 | 2024-03-14 | Talengen Int Ltd | Plasminógeno para su uso en el tratamiento de la angiocardiopatía diabética |
| WO2017161354A1 (en) * | 2016-03-17 | 2017-09-21 | Vanderbilt University | Enhancing plasmin activity to prevent soft tissue calcification |
| CN110167583A (zh) * | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
| JP7175270B2 (ja) | 2016-12-15 | 2022-11-18 | タレンゲン インターナショナル リミテッド | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
| TW201822790A (zh) | 2016-12-15 | 2018-07-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種預防和治療皮膚纖維化的方法 |
| CN110114081A (zh) | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种改善心脏病变的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| CN109125715A (zh) * | 2017-06-19 | 2019-01-04 | 深圳瑞健生命科学研究院有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
| DK3643321T3 (da) * | 2017-06-19 | 2025-08-18 | Talengen Int Ltd | Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN113597313A (zh) * | 2019-01-24 | 2021-11-02 | 先觉药业咨询公司 | 用于治疗和预防微血栓形成的纤溶酶原 |
| EP3812772B1 (en) * | 2019-10-24 | 2025-02-19 | Hôpitaux Universitaires de Strasbourg (HUS) | Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps |
| US12497607B2 (en) * | 2020-04-23 | 2025-12-16 | Previpharma Consulting Gmbh | Plasminogen for use in treating and preventing lung dysfunction |
| CN114354929A (zh) * | 2022-01-07 | 2022-04-15 | 南京鼓楼医院 | 一种用于监测人体纤溶状态的试剂盒及应用 |
| WO2025049724A1 (en) * | 2023-08-29 | 2025-03-06 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating pleural space infections and hemothorax |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994001128A1 (en) * | 1992-07-01 | 1994-01-20 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| WO2003020297A2 (en) * | 2001-09-06 | 2003-03-13 | Omnio Ab | Method of improving wound healing |
| WO2008027000A2 (en) * | 2006-08-28 | 2008-03-06 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| RU2564131C2 (ru) * | 2009-07-10 | 2015-09-27 | ТромбоДженикс НВ | Варианты плазминогена и плазмина |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2254316B1 (enExample) * | 1973-12-18 | 1977-04-22 | Choay Sa | |
| JP2764264B2 (ja) * | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| EP0682700A4 (en) * | 1993-02-05 | 1997-05-28 | Vascular Lab | USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE. |
| US20030224516A1 (en) * | 2002-06-03 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of prox-1 expression |
| US20050271636A1 (en) * | 2002-08-09 | 2005-12-08 | St. Jude Children's Research Hospital, Inc. | Diagnostic and therapeutic uses for prox 1 |
| GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| DK2056864T3 (en) * | 2006-08-28 | 2014-03-10 | Omnio Healer Ab | CANDIDATES AGAINST INFECTION |
| JP6343147B2 (ja) * | 2010-08-30 | 2018-06-13 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 狭窄病変および血栓溶解療法のための剪断による制御放出 |
| PT3233111T (pt) | 2014-12-19 | 2024-10-10 | Kedrion Biopharma Inc | Composição farmacêutica que compreende éniplasminogénio e seus usos |
| CN108463240A (zh) * | 2015-12-18 | 2018-08-28 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
-
2016
- 2016-11-02 TW TW105135535A patent/TWI801331B/zh active
- 2016-11-03 JP JP2018522753A patent/JP6878423B2/ja active Active
- 2016-11-03 CA CA3002915A patent/CA3002915C/en active Active
- 2016-11-03 CN CN201680067482.XA patent/CN108289935A/zh active Pending
- 2016-11-03 FI FIEP16861682.9T patent/FI3370760T3/fi active
- 2016-11-03 WO PCT/IB2016/001599 patent/WO2017077380A1/en not_active Ceased
- 2016-11-03 AU AU2016347863A patent/AU2016347863B2/en active Active
- 2016-11-03 RU RU2018120182A patent/RU2736831C2/ru active
- 2016-11-03 US US15/771,454 patent/US11291711B2/en active Active
- 2016-11-03 KR KR1020187015657A patent/KR102821400B1/ko active Active
- 2016-11-03 EP EP16861682.9A patent/EP3370760B1/en active Active
- 2016-11-03 BR BR112018008965A patent/BR112018008965A8/pt not_active Application Discontinuation
- 2016-11-03 MY MYPI2018000585A patent/MY199581A/en unknown
- 2016-11-03 MX MX2018005588A patent/MX2018005588A/es unknown
-
2018
- 2018-04-24 IL IL258913A patent/IL258913B/en unknown
- 2018-04-26 ZA ZA2018/02820A patent/ZA201802820B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994001128A1 (en) * | 1992-07-01 | 1994-01-20 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| WO2003020297A2 (en) * | 2001-09-06 | 2003-03-13 | Omnio Ab | Method of improving wound healing |
| WO2008027000A2 (en) * | 2006-08-28 | 2008-03-06 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| RU2564131C2 (ru) * | 2009-07-10 | 2015-09-27 | ТромбоДженикс НВ | Варианты плазминогена и плазмина |
Non-Patent Citations (1)
| Title |
|---|
| PATRICK WATTS et al. Effective Treatment of Ligneous Conjunctivitis With Topical Plasminogen, Am J Ophthalmol, 2002, Vol.133, N.4, p.451-455. * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018005588A (es) | 2018-11-09 |
| FI3370760T3 (fi) | 2025-12-05 |
| CA3002915A1 (en) | 2017-05-11 |
| EP3370760B1 (en) | 2025-10-01 |
| AU2016347863B2 (en) | 2023-11-09 |
| KR102821400B1 (ko) | 2025-06-18 |
| WO2017077380A1 (en) | 2017-05-11 |
| AU2016347863A1 (en) | 2018-06-07 |
| JP2018533589A (ja) | 2018-11-15 |
| NZ742657A (en) | 2024-04-26 |
| CA3002915C (en) | 2024-01-16 |
| BR112018008965A8 (pt) | 2019-02-26 |
| IL258913A (en) | 2018-06-28 |
| RU2018120182A3 (enExample) | 2020-04-27 |
| US20190231854A1 (en) | 2019-08-01 |
| JP6878423B2 (ja) | 2021-05-26 |
| BR112018008965A2 (pt) | 2018-11-21 |
| IL258913B (en) | 2021-12-01 |
| TW201722463A (zh) | 2017-07-01 |
| TWI801331B (zh) | 2023-05-11 |
| EP3370760A4 (en) | 2019-06-26 |
| EP3370760A1 (en) | 2018-09-12 |
| KR20180083348A (ko) | 2018-07-20 |
| US11291711B2 (en) | 2022-04-05 |
| ZA201802820B (en) | 2019-07-31 |
| MY199581A (en) | 2023-11-07 |
| CN108289935A (zh) | 2018-07-17 |
| RU2018120182A (ru) | 2019-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2736831C2 (ru) | Плазминоген-заместительная терапия при дефиците плазминогена | |
| Gando et al. | Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients | |
| Rehberg et al. | Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury | |
| EA002496B1 (ru) | Способы лечения состояний гиперкоагуляции или приобретенной недостаточности белка с | |
| Schuster et al. | Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis | |
| Waydhas et al. | High-dose antithrombin III treatment of severely injured patients: results of a prospective study | |
| Roldán et al. | Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis | |
| Zöller et al. | Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease | |
| US20090018082A1 (en) | Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma | |
| RU2606155C2 (ru) | Фактор ii и фибриноген для лечения гемостатических нарушений | |
| Qin et al. | Progress in the treatment of acute fatty liver of pregnancy and management of perioperative anesthesia review | |
| Roldán et al. | Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction | |
| Ding et al. | A good way to reduce screening for retinopathy of prematurity: Development of the ROP model in a China preterm population | |
| JP2004527554A (ja) | Ａｒｄｓの処理における修飾されたｆｖｉｉ | |
| Aihara et al. | Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors | |
| Peus et al. | Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression | |
| Yalçındağ et al. | Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement | |
| Katneni et al. | In silico features of ADAMTS13 contributing to plasmatic ADAMTS13 levels in neonates with congenital heart disease | |
| Elsayegh et al. | Incidence of Heparin Resistance during Cardio-Pulmonary Bypass in Adult Cardiac Surgery in the Era of COVID-19 | |
| JP2009520696A (ja) | 出血性ショックおよびその続発症を治療するための製剤 | |
| JP7515557B2 (ja) | 凝固異常を伴う敗血症の治療及び／又は改善のための医薬 | |
| Pomero et al. | Direct oral anticoagulants in factor VII deficiency patient | |
| RU2813699C2 (ru) | Плазминоген для лечения и профилактики микротромбоза | |
| Rogozhkina et al. | Clinical and laboratory characteristics of patients with severe COVID-19 undergoing gene engineering therapy | |
| Okuyama et al. | 49, XXXXY syndrome with unilateral renal aplasia, proteinuria, and venous thromboembolism |